Ceruvia Lifesciences, a biopharmaceutical company, announced that it has produced the world's first LSD that meets stringent "Current Good Manufacturing Practices" (CGMP) standards required by the FDA for new drug approvals and is offering to supply it at no cost to qualified researchers.
Ensuring the availability of a supply of CGMP LSD will be a key factor in advancing research into LSD's safety and efficacy for the treatment of a range of neurological, mental health and neurodevelopmental disorders, including cluster headaches, migraines, alcohol use disorder, opioid use disorder, anxiety and attention deficit disorder, according to a company press release.
